Substance

ID:1114

Names and Identifiers
Brand Name
PaxylTaractanTarasanTraquilanTruxalTruxilVetacalmTruxalettenIaractanRentovetTactaranTardanTrictal
Synonyms
ChlorprothixineChlothixenCPXChloroprothixeneChlorprothixenChlorprotixineCPTChlorprotixenChlorprothixeneAlpha-ChlorprothixeneChlorprotixeneCis-Chlorprothixene
IUPAC Traditional name
chlorprothixene
IUPAC name
[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]dimethylamine
Registration numbers
CAS Number
Properties
Physical Property
Hydrophobicity(logP)
5.2
Solubility
0.295 mg/L
Molecule Details
Drug Groups
approved
Description
Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Indication
For treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
Pharmacology
Chlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency.
Toxicity
Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
Absorption
Incomplete bioavailability.
Half Life
8 to 12 hours
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data